Wall Street brokerages predict that Repligen Co. (NASDAQ:RGEN) will announce sales of $41.33 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Repligen’s earnings. The lowest sales estimate is $40.90 million and the highest is $42.06 million. Repligen reported sales of $25.60 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 61.4%. The firm is expected to issue its next quarterly earnings results before the market opens on Thursday, February 22nd.
On average, analysts expect that Repligen will report full year sales of $41.33 million for the current financial year, with estimates ranging from $140.50 million to $141.68 million. For the next financial year, analysts anticipate that the firm will report sales of $184.79 million per share, with estimates ranging from $181.63 million to $190.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Repligen.
Several analysts have recently commented on RGEN shares. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a report on Wednesday, February 7th. Citigroup started coverage on Repligen in a report on Friday, December 8th. They set a “buy” rating and a $45.00 price objective for the company. JPMorgan Chase & Co. started coverage on Repligen in a report on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price objective for the company. Zacks Investment Research lowered Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, January 24th. Finally, Jefferies Group restated a “hold” rating and issued a $40.00 target price on shares of Repligen in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.38.
In related news, VP Howard Benjamin sold 12,729 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the completion of the transaction, the vice president now owns 36,554 shares in the company, valued at approximately $1,291,818.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 8,970 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the completion of the transaction, the chief executive officer now owns 83,613 shares of the company’s stock, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of RGEN. Lord Abbett & CO. LLC raised its stake in Repligen by 330.9% in the 2nd quarter. Lord Abbett & CO. LLC now owns 851,360 shares of the biotechnology company’s stock worth $35,280,000 after acquiring an additional 653,791 shares during the last quarter. Wells Fargo & Company MN grew its position in Repligen by 38.9% during the 4th quarter. Wells Fargo & Company MN now owns 890,607 shares of the biotechnology company’s stock worth $32,311,000 after purchasing an additional 249,451 shares during the period. Conestoga Capital Advisors LLC grew its position in Repligen by 14.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,669,562 shares of the biotechnology company’s stock worth $60,572,000 after purchasing an additional 216,330 shares during the period. Macquarie Group Ltd. grew its position in Repligen by 34.6% during the 3rd quarter. Macquarie Group Ltd. now owns 752,433 shares of the biotechnology company’s stock worth $28,833,000 after purchasing an additional 193,232 shares during the period. Finally, Vanguard Group Inc. grew its position in Repligen by 9.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after purchasing an additional 175,191 shares during the period. Institutional investors own 83.48% of the company’s stock.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.